Sex hormone binding globulin directly influences free testosterone levels and helps clinicians interpret conflicting blood test results before making TRT decisions.
Sex hormone-binding globulin, commonly known as SHBG, is a specialized transport protein produced primarily by the liver. It is not a hormone itself, and it does not generate androgenic signals on its own. Instead, it acts as a carrier molecule that binds circulating testosterone and regulates how much of the hormone is readily available to tissues throughout the body.
Understanding this transport protein is essential for interpreting hormone blood tests. Total testosterone measures the sum of all testosterone circulating in the bloodstream, regardless of whether it is free or bound to proteins. When a patient has unusually high or low SHBG levels, a standard total testosterone result can misrepresent how much active hormone is actually reaching target tissues.
This comprehensive guide examines how SHBG alters blood test interpretation, why binding levels shift across different health conditions, and how medical professionals navigate discordant lab results. It provides the physiological background, evidence grading, and clinical frameworks necessary to make sense of complex hormone panels before evaluating testosterone replacement therapy.
Please note that this guide is designed solely for educational purposes. It does not provide medical advice, diagnosis, or personalized treatment protocols. Anyone considering hormone testing or medical therapy should consult a qualified healthcare professional.
Interpreting male hormone levels requires looking beyond single numbers. The interaction between binding proteins and circulating androgens creates distinct laboratory patterns that demand careful clinical context.
The most important clinical principles regarding SHBG and testosterone evaluation include:
Evaluating these markers together helps patients and doctors avoid unnecessary lifelong treatment or premature misdiagnoses.
To understand why laboratory results can show conflicting messages, one must look at how androgens travel through the vascular system. Testosterone does not circulate as an isolated molecule in blood plasma. Because testosterone is a lipophilic steroid, it does not dissolve easily in water or blood serum.
To travel through the circulatory system, testosterone relies on carrier proteins. In adult men, circulating testosterone exists in three distinct physiological states:
Roughly 40 to 65 percent of circulating testosterone is bound tightly to SHBG. This high-affinity chemical bond prevents the testosterone molecule from easily detaching and diffusing across cell membranes. As long as testosterone is bound to SHBG, it is generally considered biologically inactive in peripheral target tissues.
Roughly 30 to 55 percent of circulating testosterone is bound loosely to albumin, the most abundant protein in blood plasma. Unlike SHBG, albumin binds testosterone with low affinity. This weak bond allows the hormone to dissociate quickly within tissue capillary beds.
Only about 1 to 3 percent of circulating testosterone remains completely unbound in blood plasma. This unbound portion is termed free testosterone. Along with the loosely bound albumin fraction, free testosterone is available to cross cell membranes, bind to intracellular androgen receptors, and trigger physiological responses.
The term bioavailable testosterone refers to the combination of free testosterone and albumin-bound testosterone. While bioavailable testosterone represents the total pool of easily dissociable hormone, clinical guidelines note that the evidence linking bioavailable testosterone to clinical deficiency is less developed than the evidence for free testosterone.
Because standard total testosterone assays measure all three pools combined, any condition that changes the concentration of SHBG will distort total testosterone. If SHBG levels drop significantly, the total storage capacity of the bloodstream shrinks. Total testosterone drops as a consequence, but the free testosterone fraction may remain entirely normal.
Conversely, if SHBG levels rise significantly, more testosterone becomes locked in high-affinity storage. Total testosterone may appear high or normal, but the actual pool of free testosterone can be severely depleted. This fundamental physiological relationship explains why clinicians must evaluate testing and biomarkers together rather than treating total testosterone as a standalone metric.
SHBG concentrations are not static. The liver adjusts its production of this transport glycoprotein in response to metabolic signals, hormone ratios, age, and systemic disease.
When evaluating hormone blood tests, clinicians look for underlying conditions that alter hepatic SHBG synthesis. These conditions generally fall into two broad clinical categories.
When liver synthesis of SHBG decreases, the blood contains fewer high-affinity binding sites. This state frequently leads to a lower total testosterone concentration, even when testicular hormone production is preserved.
Key conditions and exposures that lower SHBG include:
In men with metabolic syndrome or moderate obesity, low total testosterone is frequently a secondary consequence of suppressed SHBG. Addressing metabolic health, improving insulin sensitivity, and reviewing lifestyle factors and natural hormone support often restores both SHBG and total testosterone without the need for exogenous hormone therapy.
When hepatic synthesis of SHBG increases, the capacity for androgen binding expands. This dynamic can mask androgen deficiency by keeping total testosterone measurements within standard normal ranges while free testosterone falls.
Key conditions and exposures that raise SHBG include:
In older men, rising SHBG is a primary reason why symptoms of androgen deficiency can emerge even when total testosterone appears stable. Recognizing these secondary causes ensures that clinicians do not overlook low free testosterone in patients with seemingly adequate total hormone concentrations.
Arriving at an accurate diagnosis of hypogonadism requires a systematic clinical protocol. Medical guidelines from major endocrine organizations emphasize that hormone replacement therapy is a major clinical commitment. It should never be initiated based on isolated or conflicting laboratory numbers.
Clinicians use a step-by-step diagnostic process to evaluate discordant total testosterone and SHBG results.
Hormone testing should only occur when a patient displays consistent signs and risk factors of low testosterone. These signs include reduced sexual desire, decreased spontaneous erections, unexplained bone loss, loss of body hair, or unexplained fatigue combined with loss of muscle mass.
Guidelines explicitly recommend against testing during acute illness, recovery from trauma, or during short-term use of medications that suppress the gonadal axis, such as opioids. Testing during temporary physiological stress often generates misleadingly low results that resolve naturally once the illness passes.
Testosterone secretion follows a circadian rhythm, peaking in the early morning hours and declining toward the evening. Furthermore, food intake and oral glucose consumption suppress testosterone secretion transiently.
For these reasons, initial testing must use a fasting morning blood draw collected between 8:00 AM and 10:00 AM. If the initial total testosterone result falls below the laboratory reference range, the test must be repeated on a separate fasting morning.
Data cited by the Endocrine Society shows that approximately 30 percent of men who test low on their first morning panel test completely normal on a second measurement. Biological variability, sleep quality, stress, and previous physical exertion can all cause transient drops. A diagnosis of hypogonadism requires persistent, unequivocally low measurements on multiple occasions.
When total testosterone is unequivocal, such as levels falling below 150 ng/dL, normal free testosterone is highly improbable. In such cases, measuring free testosterone is generally unnecessary because true deficiency across all fractions is clear.
However, when total testosterone falls in a borderline zone, roughly defined as 200 to 400 ng/dL, free testosterone measurement becomes essential. Measuring free testosterone is also necessary whenever a patient presents with an SHBG-altering condition, regardless of the exact total testosterone number.
The technique used to measure free testosterone is critical. The Endocrine Society advises strongly against direct analog-based free testosterone immunoassays. These direct commercial kits are analytically inaccurate because the tracer molecules bind unpredictably to albumin and SHBG, yielding unreliable numbers.
Clinicians rely on two valid approaches:
Calculated free testosterone provides a dependable clinical estimate, provided the laboratory uses high-quality assays for the underlying markers. Clinicians must always interpret calculated results against the specific reference range provided by that laboratory.
By combining total testosterone, SHBG, and free testosterone, clinicians can categorize patients into distinct clinical patterns.
This pattern is exceptionally common in men with obesity, metabolic syndrome, or mild insulin resistance. The suppressed SHBG lowers the total hormone storage pool, dragging total testosterone below 300 ng/dL. However, free testosterone remains within the normal reference interval, and the patient may report few classic symptoms of deficiency.
In this scenario, initiating hormone therapy is generally inappropriate. The primary clinical focus should involve addressing insulin resistance, improving nutrition, and reducing visceral adiposity to allow SHBG synthesis to normalize.
A patient presents with total testosterone between 250 and 350 ng/dL alongside mild metabolic syndrome or thyroid disease. Measuring SHBG and calculating free testosterone reveals whether the bioavailable hormone pool is genuinely compromised. If free testosterone is normal, clinical management focuses on the underlying condition rather than immediate hormone replacement.
This pattern often appears in aging men, patients with chronic liver conditions, or men using anticonvulsant medications. Total testosterone may measure a reassuring 450 ng/dL, but an elevated SHBG locks up a disproportionate percentage of the hormone.
As a result, calculated free testosterone falls well below the lower reference limit. If the patient exhibits unequivocal symptoms of deficiency, this pattern represents true functional hypogonadism that total testosterone testing alone would have missed.
A patient tests at 240 ng/dL on an initial test taken after a night of poor sleep or during a period of acute work stress. A repeat fasting test two weeks later shows a total testosterone of 420 ng/dL. This pattern illustrates natural biological variation and demonstrates why guidelines mandate confirmatory testing before considering clinical therapy.
A patient undergoing a general wellness screening shows a total testosterone of 270 ng/dL, an SHBG of 14 nmol/L, a normal free testosterone, and zero physical or sexual symptoms. Because clinical guidelines require both symptoms and biochemical deficiency, this pattern does not warrant hormone replacement therapy.
A patient presents with an SHBG above 80 or 100 nmol/L, severe fatigue, erectile dysfunction, and low free testosterone, despite a total testosterone of 600 ng/dL. Blood work reveals elevated luteinizing hormone (LH), confirming that the pituitary gland is attempting to drive hormone output higher to compensate for low free hormone availability. This pattern indicates true primary gonadal insufficiency within the context of severe protein binding.
Confirming low free testosterone is not the final step. A comprehensive evaluation requires determining why the deficiency exists. Clinicians order additional pituitary and metabolic markers to differentiate primary testicular failure from secondary pituitary or hypothalamic suppression before discussing lifelong testosterone therapy and clinical research.
Clinical guidelines and epidemiological studies offer clear insights into how total testosterone, SHBG, and free testosterone interact. Understanding the hierarchy of medical evidence helps separate established diagnostic rules from preliminary findings.
The Endocrine Society Clinical Practice Guideline represents the international benchmark for evaluating male hypogonadism. The guideline firmly establishes that total testosterone is the primary initial screening test, but it recognizes the severe limitations of total testosterone when binding proteins fluctuate.
Key recommendations from the Endocrine Society include:
The American Urological Association (AUA) guidelines also emphasize using at least two early morning total testosterone measurements drawn on separate days. The AUA similarly recommends measuring SHBG and free testosterone when total testosterone is borderline or when clinical symptoms conflict with total hormone levels.
Large population studies provide real-world data on how binding proteins affect clinical symptoms. The European Male Ageing Study (EMAS) evaluated thousands of community-dwelling men to examine the relationship between hormone fractions and symptoms of androgen deficiency.
The EMAS analysis revealed several vital insights:
These findings support the clinical practice of relying on free testosterone when evaluating men with metabolic conditions or borderline total testosterone levels.
While standard clinical guidelines focus on typical reference ranges, newer observational research has highlighted what occurs at extreme biological limits.
A 2026 clinical investigation evaluated a cohort of 20 men presenting with markedly elevated SHBG concentrations exceeding 100 nmol/L. Among these 20 men, 15 met the Endocrine Society criteria for primary hypogonadism. Despite having total testosterone levels that were well within the normal range, or even above the upper reference limit, their free testosterone levels were severely depressed.
Furthermore, these men demonstrated elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations. The elevated gonadotropins confirmed that the pituitary gland recognized the physiological deficit in free androgen signaling and attempted to stimulate testicular production.
While this study represents a small, selected clinical series rather than a broad population estimate, it illustrates an important principle. Total testosterone can be entirely misleading in individuals with extreme protein elevation, making free testosterone and gonadotropin testing indispensable.
Evaluating male hormonal health requires a complete panel of interacting biomarkers. No single test tells the entire story. A comprehensive evaluation allows clinicians to understand male hormonal function and trace symptoms back to their underlying origin.
The following biomarkers form the standard laboratory evaluation for male hormone health:
Total testosterone measures all circulating testosterone in the blood, including fractions bound to SHBG, albumin, and circulating freely. It serves as the primary initial screening test for androgen deficiency.
Measurements should always be taken between 8:00 AM and 10:00 AM after an overnight fast. Values below approximately 264 to 300 ng/dL are generally considered low, but results must always be interpreted alongside clinical symptoms and confirmed with repeat testing.
SHBG is the primary high-affinity binding protein for testosterone and dihydrotestosterone. Measuring SHBG is necessary to interpret total testosterone accurately in men with obesity, type 2 diabetes, thyroid disease, liver conditions, or advanced age.
A standard adult male reference range is typically between 10 and 50 nmol/L, though ranges vary across laboratories. Values below 15 nmol/L suggest metabolic suppression, while values above 50 nmol/L suggest increased protein binding that may depress free testosterone.
Albumin is the most abundant protein in blood plasma and binds testosterone with low affinity. Measuring serum albumin is required to calculate free testosterone accurately using standard mathematical formulas.
A normal albumin level ranges from 3.5 to 5.0 g/dL. Significant shifts in albumin, caused by kidney disease, liver dysfunction, or severe malnutrition, alter the bioavailable hormone fraction.
Free testosterone measures the unbound fraction of circulating hormone that is immediately available to enter target cells. It is indicated whenever total testosterone is borderline (200 to 400 ng/dL) or when SHBG-altering conditions are present.
Reference intervals depend entirely on whether the laboratory uses equilibrium dialysis or mathematical calculation. Results must be interpreted strictly against the reference interval of the specific assay used.
Luteinizing hormone is secreted by the anterior pituitary gland to stimulate Leydig cells in the testes to produce testosterone. When combined with testosterone measurements, LH allows clinicians to distinguish between primary and secondary hypogonadism.
Follicle-stimulating hormone is also released by the anterior pituitary gland and acts primarily on Sertoli cells in the testes to support spermatogenesis. Elevated FSH levels suggest impaired sperm production or testicular damage, while low FSH indicates central hypothalamic-pituitary suppression.
Prolactin is a pituitary hormone that, when markedly elevated (hyperprolactinemia), suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH). This suppression leads directly to secondary hypogonadism.
Clinicians measure prolactin when investigating low LH and low testosterone to rule out prolactin-secreting pituitary adenomas or medication-induced hyperprolactinemia.
Iron overload disorders, such as hereditary hemochromatosis, cause excess iron deposition in both pituitary tissue and testicular tissue. This iron accumulation is a recognized cause of secondary hypogonadism.
Measuring serum ferritin and transferrin iron saturation helps clinicians identify hemochromatosis early, allowing for systemic treatment before permanent endocrine damage occurs.
Navigating hormone testing and potential therapy requires open, informed communication with a qualified physician, endocrinologist, or urologist. Patients should seek clarity regarding the accuracy of their tests, the underlying causes of their numbers, and the broader clinical picture.
Consider discussing the following evidence-based questions during your clinical consultation:
Approaching your appointment with these questions ensures that clinical decisions are grounded in comprehensive evidence rather than isolated laboratory values.
Nutritional and lifestyle modifications can influence SHBG, but their impact depends entirely on the root cause of the elevation. When high SHBG is driven by severe caloric restriction, extreme low-carbohydrate diets, or excessive endurance training, increasing caloric intake and balancing macronutrients can help normalize hepatic protein production.
However, if elevated SHBG is caused by biological aging, genetic polymorphisms, hyperthyroidism, or chronic liver disease, dietary changes alone will not significantly lower it. In those cases, clinical management focuses on addressing the underlying medical condition rather than attempting to force SHBG down through lifestyle interventions.
Exogenous testosterone administration typically causes a moderate decrease in circulating SHBG concentrations. Androgens exert an inhibitory effect on hepatic SHBG synthesis.
When a patient begins therapeutic testosterone administration, the influx of exogenous androgens signals the liver to reduce SHBG production. This decrease expands the clearance rate of testosterone and increases the proportion of circulating free hormone.
Clinicians frequently monitor SHBG alongside free testosterone during ongoing therapy to ensure that dosage adjustments account for these dynamic binding shifts.
Reference ranges for free testosterone vary substantially because laboratories utilize different measurement methodologies and mathematical algorithms. A direct equilibrium dialysis assay measures physical hormone mass in picograms per milliliter (pg/mL), whereas calculated free testosterone relies on equations that incorporate total testosterone, SHBG, and albumin.
Furthermore, different mathematical formulas, such as the Vermeulen equation versus the Sodergard formula, yield slightly different numerical estimates. Because international standardization across all free testosterone assays has not yet been achieved, a numerical result from one laboratory cannot be compared directly to the reference interval of another. Clinicians must always interpret free testosterone against the specific methodology and reference interval established by the testing facility.
Bioavailable testosterone includes both free testosterone and the weakly bound albumin fraction, representing all hormone that can theoretically dissociate in tissue capillary beds. While bioavailable testosterone provides useful physiological insight, major clinical guidelines prioritize free testosterone.
The clinical evidence connecting low free testosterone to documented symptoms and long-term health outcomes is significantly more established than the evidence for bioavailable testosterone. Consequently, standard clinical guidelines recommend assessing free testosterone via equilibrium dialysis or validated calculations when total testosterone is borderline or when binding proteins are altered.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
